APM - Aptorum Group Ltd Class A

APM - Aptorum Group Ltd Class A

https://www.aptorumgroup.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 3 days ago • score: 0.21

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Aptorum Group Limited ( NASDAQ: APM ) ( "Aptorum Group" or "Aptorum" ) , a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ( "DiamiR" ) , a ...

Aptorum Group Stock Sinks After Hours Following 235% Thursday Surge - ( APM )

Benzinga • 3 weeks, 3 days ago • score: -0.14

Aptorum Group Limited APM shares declined 33.18% to $2.84 in after-hours trading session on Friday following Thursday's explosive 234.65% rally. According to Benzinga Pro data, Aptorum closed the regular trading session at $4.25. Check out the current price of APM stock here.

Why Is Nano-Cap Aptorum Stock Rallying On Thursday? - Aptorum Group ( NASDAQ:APM )

Benzinga • 3 weeks, 4 days ago • score: 0.21

Aptorum shares trade higher on 168.16 million volume vs 3.25 million average. DiamiR gains CLEP approval for APOE Genotyping test in New York. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test - Aptorum Group ( NASDAQ:APM )

Benzinga • 3 weeks, 4 days ago • score: 0.20

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- DiamiR Biosciences Corp. ( "DiamiR" ) , a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited APM ( "Aptorum Group" or "Aptorum" ) , a clinical ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.

52W High

$4.47

52W Low

$0.46

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.02

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.46

EV/Revenue (<3 favorable)

31.22

P/S (TTM) (<3 favorable)

23.35

P/B (<3 favorable)

0.63

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

19.48%

Institutions (25–75% balanced)

0.82%

Shares Outstanding

5,346,800

Float

3,404,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

5,250

EPS (TTM)

-0.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

0.0485

Previous

0.0387

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025